| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Eldecalcitol binds to the vitamin D receptor (VDR) with less affinity than 1,25(OH)2D3 but binds to vitamin D-binding protein with higher affinity, resulting in a long half-life in plasma. It is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. Its anti-tumor effects are mediated by suppressing GPx-1.
|
|---|---|
| ln Vitro |
Eldecalcitol is non-cytotoxic and can decrease LPS (5 μg/mL)-induced cell death (0.5–50 nM; 24 hours) [2]. By activating Eldecalcitol (0.5-50 nM; 24 h), Eldecalcitol (5 nM; 24 h) exhibits anti-pyroptotic ability and induces dose-wise decrease of NLRP3, caspase-1, and IL. LPS-induced pyroptosis is inhibited by Nrf2 and its effector molecule HO-1[2]. Eldecalcitol (0.04–40 nM; 0-48 h) prevents SCC-15 and CAL-27 cells from proliferating and migrating [3]. Cell cycle curve expression at -1β is induced by edecalcitol (0.4 nM; 48 h) [3]. G0/G1 phase, as well as by preventing cells from expressing glutathione peroxidase, or GPx-1 [3].
In vitro, eldecalcitol displays anti-tumor effects, inhibiting cell proliferation and migration and inducing apoptosis by suppressing GPx-1. It inhibits bone resorption in cell-based models. It has a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. |
| ln Vivo |
By inhibiting GPx-1 (glutathione peroxidase), eldecalcitol (0.5 μg/kg; channel; twice weekly for 4 weeks) has anticancer effects [3]. Eldecalcitol, a more potent vitamin D3 analogue that promotes focal bone (miniature model) and is more efficient than bone Chetriol in inhibiting bone resorption, (10, 30, or 90 ng/kg; lateral; 5 times weekly for 12 weeks).
In vivo, eldecalcitol is effective in increasing bone mass and enhancing bone strength in rodents. It is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency. It has a safety profile similar to alfacalcidol. It is an orally active agent. |
| Enzyme Assay |
In vitro receptor binding assays for eldecalcitol typically involve evaluating its affinity for the vitamin D receptor (VDR) and vitamin D-binding protein (DBP) using radioligand binding or surface plasmon resonance (SPR). Competitive binding assays are performed with varying concentrations of the compound. Binding affinity (Ki or Kd) values are calculated from displacement curves.
|
| Cell Assay |
Western Blot analysis [2]
Cell Types: Human gingival fibroblasts (HGFs) Tested Concentrations: 0, 0.5, 5 and 50 nM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with LPS treatment group, TLR4, NLRP3, caspase-1 p20, ASC and GSDMD-N levels were diminished in a dose-dependent manner. LPS-induced IL-1β and IL-18 release was diminished to normal levels. Cell proliferation assay [3] Cell Types: SCC-15 and CAL-27 Cell Tested Concentrations: 0, 0.04, 0.4, 4 and 40 nM Incubation Duration: 6, 8, 12, 24, 48 hrs (hours) Experimental Results: Inhibition of cell viability using 0.4 nM , OSCC cells reached 50% within 24 hrs (hours). Cell proliferation analysis [3] Cell Types: OSCC Cell Tested Concentrations: 0.4 nM Incubation Duration: 48 hrs (hours) Experimental Results: The proportion of late-stage apoptotic cells increased from 7.1% to 16.1%. Bax and caspase-3 were upregulated, and Bcl-2 was downregulated. Dramatically triggers apoptosis of SCC-15 and CAL-27 cells. Cell-based assays for eldecalcitol involve culturing osteoblasts, osteoclasts, or cancer cell lines in appropriate media. Cells are treated with eldecalcitol at concentrations ranging from 0.1 nM to 1 µM for 24-72 hours. Cell proliferation is assessed by MTT or BrdU incorporation. Osteoclast differentiation and bone resorption are measured by TRAP staining and pit formation assays. Apoptosis is evaluated by flow cytometry. |
| Animal Protocol |
Animal/Disease Models: Mouse xenograft tumor model (male athymic nude BALB/c mouse) [3]
Doses: 0.5 μg/kg Route of Administration: po (oral gavage); [4]. Twice a week for 4 weeks. Experimental Results: diminished tumor growth rate, down-regulated the expression levels of PCNA and MMP-2 in tumors, and up-regulated Bax expression. Resulting in diminished proliferation, inhibition of migration, and promotion of apoptosis. Animal/Disease Models: Ovariectomized (OVX) rat model [4] Doses: 10, 30 or 90 ng/kg Route of Administration: po (oral gavage); 5 times per week for 12 weeks Experimental Results: Lumbar spine and femur BMD in a dose-dependent manner way increased. The stimulation of local bone formation begins without prior bone resorption, a process called bone micromodelling. In vivo animal experiments for eldecalcitol typically involve administration to ovariectomized rat models of osteoporosis via oral gavage. Bone mineral density is measured by DEXA. Bone strength is assessed by mechanical testing. Fracture healing and bone turnover markers are evaluated. Anti-tumor efficacy is evaluated in xenograft mouse models. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues. |
| ADME/Pharmacokinetics |
Eldecalcitol (molecular weight ~500) is orally active. It binds to vitamin D-binding protein with higher affinity than 1,25(OH)2D3, resulting in a long half-life in plasma. It is metabolized in the liver and excreted via bile and urine. Detailed pharmacokinetic parameters are available in clinical pharmacology literature. It supports once-daily dosing.
|
| Toxicity/Toxicokinetics |
Eldecalcitol has a safety profile similar to alfacalcidol. Common side effects may include hypercalcemia, gastrointestinal effects, and skin reactions. It is contraindicated in patients with hypercalcemia or vitamin D toxicity. Comprehensive toxicological evaluation has been conducted in preclinical and clinical studies. It is generally well-tolerated in clinical settings.
|
| References |
|
| Additional Infomation |
1α,25-Dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 is a hydroxycalcitrol, specifically calcitriol with a 3-hydroxypropoxy group at the 2-position. It is a metabolite. It is a tetraol, belonging to the vitamin D3 family, and is also a hydroxycalcitrol. It is functionally related to calcitriol. In an estrogen-deficient rat model of osteoporosis, the vitamin D analog edicalcium (ED-71) was more effective than alfacalcidol in inhibiting bone resorption. Edicalcium effectively and safely increased bone mineral density (BMD) in the lumbar spine and hip of osteoporotic patients receiving concurrent vitamin D3 supplementation. [Pharmaceutical Indications] [Studied for the treatment of osteoporosis.]
Mechanism of Action Edecalciferol [1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3] is an analog of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], with a hydroxypropoxy residue at the 2β position. Edecalciferol can effectively increase bone mass and enhance bone strength in rodents. It has a lower affinity for the vitamin D receptor (VDR) than 1,25(OH)2D, but a higher affinity for vitamin D-binding proteins, thus exhibiting a longer half-life in plasma. Eldecalcitol (CAS#: 104121-92-8) is an orally active vitamin D3 analogue for osteoporosis treatment. It inhibits bone resorption and increases bone mineral density. It also displays anti-tumor effects. It binds to VDR and DBP. It is approved for osteoporosis in Japan and other countries. |
| Molecular Formula |
C30H50O5
|
|---|---|
| Molecular Weight |
490.725
|
| Exact Mass |
490.365
|
| Elemental Analysis |
C, 73.43; H, 10.27; O, 16.30
|
| CAS # |
104121-92-8
|
| Related CAS # |
Eldecalcitol-d6
|
| PubChem CID |
6918141
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
655.7±55.0 °C at 760 mmHg
|
| Melting Point |
126-128ºC
|
| Flash Point |
350.3±31.5 °C
|
| Vapour Pressure |
0.0±4.5 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
5.84
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
784
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@@]1([H])C([H])([H])C([H])([H])[C@@]2([H])/C(=C(\[H])/C(/[H])=C3\C(=C([H])[H])[C@]([H])([C@@]([H])([C@@]([H])(C\3([H])[H])O[H])OC([H])([H])C([H])([H])C([H])([H])O[H])O[H])/C([H])([H])C([H])([H])C([H])([H])[C@]12C([H])([H])[H]
|
| InChi Key |
FZEXGDDBXLBRTD-AYIMTCTASA-N
|
| InChi Code |
InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1
|
| Chemical Name |
(1R,2R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
|
| Synonyms |
Eldecalcitol; ED 71; ED-71; ED71; Edirol; 1,25-dihydroxyvitamin D3; 2-(3-Hydroxypropoxy)calcitriol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Methanol: ~8.3 mg/mL (~17 mM)
DMSO: ~3.3 mg/mL (~6.8 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0378 mL | 10.1889 mL | 20.3778 mL | |
| 5 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL | |
| 10 mM | 0.2038 mL | 1.0189 mL | 2.0378 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis
CTID: UMIN000007070
Phase: Status: Complete: follow-up complete
Date: 2015-03-31
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA